Results 171 to 180 of about 26,259 (260)

Bispecific Antibodies: Strategies Available to Optimize Their Safe Delivery in Patients with Multiple Myeloma. [PDF]

Antibodies (Basel)
Giles HV, Kishore B.
europepmc   +1 more source

Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis

American Journal of Hematology, Volume 101, Issue 8, Page 1928-1937, August 2026.
ABSTRACT Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real‐world study to comprehensively report muco‐cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow‐up reported enabling better efficacy and ...
Murali Janakiram, Carlyn R. Tan, Hira Mian, Chiung‐Yu Huang, Rakesh Popat, Joaquín Martínez‐Lopez, Efsthathios Kastritis, Wee‐Joo Chng, Prashant Kapoor, Mrugakshi Dave, Susan Bal, Laurent Garderet, Andre De Menezes Silva Corraes, Christine Riedhammer, Torsten Steinbrunn, Magdalene Corona, Chandramouli Nagarajan, Hermann Einsele, Tom Martin, Amrita Krishnan, Yi Lin, Nadine Abdullah, Niels Abildgaard, Ingerid Abrahamsen, Melissa Alsina, Kenneth Anderson, Hervé Avet‐Loiseau, Ashraf Badros, Nizar Jacques Bahlis, Susan Bal, Rahul Banerjee, Dina Ben‐Yehuda, Jesús G. Berdeja, Michele Cavo, Ajai Chari, Wen‐Ming Chen, Marta Chesi, Wee‐Joo Chng, Yael Cohen, Adam Cohen, Gordon Cook, Luciano Costa, Andrew Cowan, Carlos Fernández de Larrea, Benjamin Derman, Juan Du, Hermann Einsele, Gösta Gahrton, Francesca Gay, Sergio A. Giralt, Simon Harrison, J Jean‐Luc Harousseau, Joy Ho, Doris Hansen, Maung Myo Htut, Andrzej J. Jakubowiak, Murali Janakiram, Prashant Kapoor, Efstathios Kastritis, Jonathan Kaufman, Kihyun Kim, Amrita Krishnan, Shaji Kumar, Chara Kyriakou, Xavier Leleu, Yi Lin, Sagar Lonial, Matthew frigault, Johan L. Lund, Elias Mai, Angelo Maiolino, Elias Mai, Angelo Maiolino, Sireesha Asoori Maringanti, Thomas Martin, Joaquin Martinez‐Lopez, María‐Victoria Mateos, Giampaolo Merlini, Hira Mian, Joseph Mikhael, Monique Minnema, Philippe Moreau, Gareth Morgan, Nikhil Munshi, Omar Nadeem, Chandramouli Nagarajan, Ajay Nooka, Michael O'Dwyer, Rimke Oostvogel, Alberto Orfao, Paula Rodriguez Otero, Darren Pan, Krina Patel, Rashesh Popat, Noemí Puig   +94 more
wiley   +1 more source

Saudi experts statement on advancing multiple myeloma treatment: the evolving role of bispecific antibodies. [PDF]

Front Med (Lausanne)
Alotaibi GS, Alsaeed A, Alahmadi M, Alamer A, Al Saleh AS, Barefah AS, Alhayli S, Mutahar EY, Abduljalil O, Kiwan H, Alhejazi A.   +10 more
europepmc   +1 more source

Igniting cold tumors: reprogramming the tumor immune microenvironment with dual-payload ADCs in combination with PD-L1&4-1BB bispecific antibodies. [PDF]

J Immunother Cancer
Pan J, Yuan X, Yu H, Liu Z, Chen S, Zhu F, Shang Y, Hong S, Han X, Zhu Z, Jin T, Pan Y, Zhou S.   +12 more
europepmc   +1 more source

Comparative Cardiovascular Safety and Exploratory Bleeding Outcomes of Ibrutinib, Acalabrutinib, and Zanubrutinib in Mantle Cell Lymphoma: A Propensity Score‐Matched Real‐World Analysis

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Bruton tyrosine kinase inhibitors are central to the treatment of relapsed or refractory mantle cell lymphoma, but cardiovascular and bleeding toxicities influence treatment selection. Ibrutinib has been associated with atrial fibrillation/flutter and other cardiovascular adverse events, whereas second‐generation covalent BTK ...
Anna Homeniuk, Amrit Sandhu, Leena Abdalla, Anas Atrash   +3 more
wiley   +1 more source

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 452-464, August 2026.
ISB 2001 is a trispecific antibody that binds to two tumor‐associated antigens (TAA), CD38 and BCMA, and crosslinks to CD3 on T cells resulting in T cell‐mediated cytotoxicity of tumor cells expressing these TAAs. ISB 2001 is currently being tested in relapsed and/or refractory multiple myeloma (RRMM) patients in the first‐in‐human (FIH) TRIgnite‐1 ...
Vinu Chandralayam Ayyappa Menon, Tomomi Matsuura, Beata Holkova, Girish S. Gudi, Adam Drake, Maria Pihlgren, Piet H. van der Graaf, Sunitha GN, Andrew Garton, Mario Perro, Cyril Konto, Lida Pacaud   +11 more
wiley   +1 more source

To substitute or not? A systematic review of immunoglobulin replacement therapy in multiple myeloma patients treated with bispecific antibodies. [PDF]

Front Immunol
Paulsen JS, Slørdahl TS.
europepmc   +1 more source

Integrin α5β1 in pancreatic ductal adenocarcinoma: Tumour‒stroma crosstalk, hypoxia and therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
ITGA5/integrin α5β1 promotes PDAC progression by integrating fibronectin‐dependent adhesion, hypoxia‐associated ECM remodelling, pancreatic stellate cell/cancer‐associated fibroblast activation, desmoplasia and tumour‒stroma crosstalk. These processes contribute to impaired drug delivery and therapeutic resistance.
Chenzhe Ma, Yingying Wang, Yumin Li
wiley   +1 more source

Structural stability of symmetric bispecific antibodies: a case study showing potential compromise near linker regions. [PDF]

Sci Rep
Ingavat N, Kok YJ, Dzulkiflie N, Min LJ, Xinhui W, Low KN, But KP, Anajao A, Ping LH, Ong HK, Mahfut FB, Yang Y, Bi X, Zhang W.   +13 more
europepmc   +1 more source